Why disconnected RWE platforms are costing you time, money, and credibility

Real-world evidence (RWE) leaders know the pressure is on. Regulators demand reproducibility and transparency. Payers want faster, more credible insights. Internal teams rely on RWE to guide trial design, go/no-go decisions, and launch strategies.

But many organizations are stuck with a patchwork of disconnected tools for ingestion, computation, and visualization. What looks like a workable short-term fix quickly creates inefficiencies, compliance risks, and hidden costs that multiply with every study.

The cost of fragmented RWE analytics workflows

It’s 7:30 a.m. and your inbox is already full. A payer team wants evidence for a formulary submission. Regulatory affairs is asking for methodology from a six-month-old study. Your analysts are pinging you because they can’t reproduce results across the two analytics platforms your teams use.

Fragmented RWE analytics workflows create three critical failures: analysts waste time moving data across silos instead of analyzing it, IT teams support duplicative environments that inflate costs, and compliance teams can't produce audit trails when regulators demand them. These inefficiencies compound with every study.

The hidden costs are steep:

• Delays that push back submissions and market access.
• Rising budgets as teams duplicate effort across tools and functions.
• Lost credibility when inconsistencies creep into evidence packages.

Why RWE pharma and biotech teams face mounting pressure

By noon, you’re in a leadership meeting. Market access stresses that payers are tightening evidence requirements. Regulatory reminds everyone that the FDA and EMA are raising expectations for transparency and reproducibility. The CEO asks why competitors are moving faster with their RWE-supported submissions.

This pressure isn’t unique to your organization. Analysts project global RWE spending to grow in double digits annually, as pharma and biotech companies invest in data partnerships, platforms, and analytics. But too often, these investments fail to deliver because workflows remain fragmented.

Research shows data scientists still spend up to 80% of their time preparing and managing data rather than analyzing it. That inefficiency translates directly into lost time, inflated study budgets, and missed opportunities to influence regulatory and payer decisions. For executives, it means ballooning costs and frustration that RWE investments aren’t delivering the scale or impact the business requires.

What was once “good enough” is now a liability. In a market that rewards speed, scale, and credibility, disconnected platforms are simply too costly to sustain.

How a real-world evidence platform changes daily operations

Now imagine the day plays out differently.

It’s 7:30 a.m. and instead of scrambling to reconcile outputs from half a dozen systems, your teams log into Domino. Data from diverse sources is harmonized once. Pipelines built in R, Python, or SAS are reused across studies. Every step is automatically traceable. Audit trails are ready by design, so compliance is never a scramble.

By noon, the leadership conversation has shifted. Instead of debating delays and bottlenecks, you’re showing interactive dashboards that regulators and payers can trust. Stakeholders explore live evidence via interactive apps instead of static PDFs, accelerating reviews and decisions.

By day’s end, the picture is different. The evidence requests are answered, the audit fire drills are gone, and your analysts have delivered insights that are reusable, compliant, and ready for submission. What used to be a patchwork of tools and workarounds has become a single, governed environment that scales effortlessly across therapeutic areas and teams.

The organizations pulling ahead are rethinking their RWE foundation. Instead of patching together siloed tools, they are adopting platforms that unify end-to-end workflows. Domino delivers exactly that: a single, secure environment where submission-ready workflows, built-in traceability, and reproducible science are standard.

With Domino, RWE teams can:

• Accelerate time-to-insight by moving from raw data to regulatory-grade evidence without redundant handoffs.
• Ensure compliance with automated traceability, versioning, and audit trails that are ready whenever regulators ask.
• Scale globally by building validated pipelines once in R, Python, or SAS, and reusing them across studies, functions, and therapeutic areas.
• Empower stakeholders by delivering interactive, self-service apps instead of static PDFs.

The outcomes are clear: faster study execution, reduced infrastructure overhead, and greater credibility with regulators and payers. For executives, Domino transforms RWE into a growth driver, ensuring stronger returns on investments and the ability to scale programs with confidence.

Building scalable RWE analytics infrastructure

Domino offers a smarter path forward. By unifying workflows in a reusable, compliant platform, RWE leaders can transform daily fire drills into seamless operations: faster insights in the morning, more confident decisions at midday, and submission-ready evidence by day’s end.

This is how Domino eliminates hidden costs and unlocks the full value of RWE, turning evidence into a true strategic advantage.

See how Domino can help you scale RWE with speed, compliance, and confidence.